LeanBio Therapeutics, Inc. — SEC Form D Filing
LeanBio Therapeutics, Inc. filed an SEC Form D on October 22, 2026 in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 22, 2026
- Round stage
- Seed, as the company is leveraging SEC Rule 506(b) equity financing to establish early operational capacity and expand service offerings.
- Industry
- Biotechnology
- Website
- https://leanbio.net
What the company does
Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Biotechnology and pharmaceutical companies struggle with the complex, capital-intensive process design and scalable manufacturing required to bring novel biologic drugs to market.
Solution
LeanBio Therapeutics provides specialized contract development and manufacturing services to design, optimize, and produce biopharmaceutical products for drug developers.
Why now
The explosion of novel biologics pipeline candidates requires flexible, specialized biomanufacturing capacity that emerging biotech firms cannot efficiently build in-house.
Source: SEC EDGAR Form D filing